Predicting severity of haemophilia A and B splicing mutations by information analysis

Haemophilia

Volumn 12, Issue 3, 2006, Pages 258-262

  von Kodolitsch, Y ^a   Berger, J ^a   Rogan, P K ^b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

F8c; F9; Information theory; mRNA splicing; Mutation analysis; Phenotype

Indexed keywords

MESSENGER RNA;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DONOR SITE; GENE MUTATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA SPLICING;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFORMATION THEORY; MUTATION; PHENOTYPE; RNA SPLICE SITES; RNA SPLICING; RNA, MESSENGER;

EID: 33645957317     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01216.x     Document Type: Article

References (14)

1. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmakokinetik dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
2. Fakharzadeh SS, Kazazian HHJ. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 2000; 26: 167-71.
3. Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: Prospective clinical trials. Haematologica 2000; 85: 2-5.
4. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe hemophilia. Br J Haematol 2001; 112: 561-5.
5. Krawczak M, Cooper DN. The human gene mutation database. Trends Genet 1997; 13: 121-2.
6. Rogan PK, Schneider TD. Using information content and base frequencies to distinguish mutations from genetic polymorphisms in splice junction recognition sites. Hum Mutat 1995; 6: 74-6.
7. Rogan PK, Faux BM, Schneider TD. Information analysis of human splice site mutations. Hum Mutat 1998; 12: 153-71.
8. Allikmets R, Wassermann WW, Hutchinson A et al. Organization of the ABCR gene: Analysis of promotor and splice junction sequences. Gene 1998; 215: 111-22.
9. von Kodolitsch Y, Pyeritz RE, Rogan PK. Splice site mutations in atherosclerosis candidate genes: Relating individual information to phenotype. Circulation 1999; 100: 693-9.
10. David D, Moreira I, Morais S, de Deus G. Five novel factor IX mutations in unrelated hemophilia B patients. Hum Mutat 1998; 1 (Suppl.): S301-3.
11. Ketterling RP, Drost JB, Scaringe WA et al. Reported in vivo splice site mutations in the factor IX gene: Severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. Hum Mutat 1999; 13: 221-31.
12. Eyster ME, Lewis JH, Shapiro SS et al. The Pennsylvania hemophilia program 1973-1978. Am J Hematol 1980; 9: 277-86.
13. Jenicek M. Foundations of Evidence-Based Medicine. New York, NY: Taylor and Francis, 2003; 125-6.
14. Maddalena A, Bale S, Das S, Grody W, Richards SP. Technical standards and guidelines: Molecular genetic testing for ultra-rare disorders. Genet Med 2005; 7: 571-83.